These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 31230088

  • 1. Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer.
    Wondergem M, Jansen BHE, van der Zant FM, van der Sluis TM, Knol RJJ, van Kalmthout LWM, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN.
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1911-1918. PubMed ID: 31230088
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Aug; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management.
    Song H, Harrison C, Duan H, Guja K, Hatami N, Franc BL, Moradi F, Aparici CM, Davidzon GA, Iagaru A.
    J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
    [Abstract] [Full Text] [Related]

  • 4. 18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy.
    Mena E, Lindenberg ML, Turkbey IB, Shih JH, Harmon SA, Lim I, Lin F, Adler S, Eclarinal P, McKinney YL, Citrin D, Dahut W, Wood BJ, Krishnasamy V, Chang R, Levy E, Merino M, Pinto P, Eary JF, Choyke PL.
    J Nucl Med; 2020 Jun; 61(6):881-889. PubMed ID: 31676732
    [Abstract] [Full Text] [Related]

  • 5. Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer.
    Jansen BHE, Jansen RW, Wondergem M, Srbljin S, de Klerk JMH, Lissenberg-Witte BI, Vis AN, van Moorselaar RJA, Boellaard R, Hoekstra OS, Oprea-Lager DE.
    J Nucl Med; 2020 Feb; 61(2):210-216. PubMed ID: 31481580
    [Abstract] [Full Text] [Related]

  • 6. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
    Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B.
    Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
    [Abstract] [Full Text] [Related]

  • 7. Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
    Meijer D, Jansen BHE, Wondergem M, Bodar YJL, Srbljin S, Vellekoop AE, Keizer B, van der Zant FM, Hoekstra OS, Nieuwenhuijzen JA, Dahele M, Vis AN, Oprea-Lager DE.
    PLoS One; 2020 Aug; 15(10):e0239414. PubMed ID: 33021980
    [Abstract] [Full Text] [Related]

  • 8. [18F]DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA < 0.5 ng/mL.
    Perry E, Talwar A, Taubman K, Ng M, Wong LM, Booth R, Sutherland TR.
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2038-2046. PubMed ID: 33399941
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Changes in Management After 18F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes.
    Ng M, Guerrieri M, Wong LM, Taubman K, Sutherland T, Benson A, Byrne G, Koschel S, Yap K, Starmans M, Ong G, Macleod C, Foo M, Chao M.
    J Nucl Med; 2022 Sep; 63(9):1343-1348. PubMed ID: 35058320
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
    Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, Eisenberger M, Carducci M, Fan H, Dannals RF, Chen Y, Mease RC, Szabo Z, Pomper MG, Cho SY.
    Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial.
    Koschel S, Taubman K, Sutherland T, Yap K, Chao M, Guerrieri M, Benson A, Starmans M, Byrne G, Ong G, Macleod C, Foo M, Wong LM, Gyomber D, Ng M.
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3712-3722. PubMed ID: 33852051
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.